Bicyclol

Bicyclol is a hepatoprotective agent.^1,2,3,4 It has antiviral activity against hepatitis B (HBV), reducing viral DNA and the secretion of the HBV antigens HBsAg and HBeAg by 59 and 35%, respectively, in infected 2.2.15 HepG2 cells.¹ In vivo, bicyclol reduces duck HBV (DHBV) DNA in DHBV-infected ducks at doses ≥0.4 g/kg. It also reduces the expression of TNF-α and the accumulation of lymphocytes in the liver in a mouse model of liver injury induced by concanavalin A (Item No. 14951).² Oral administration of bicyclol prior to injection of diethylnitrosamine (DEN) and phenobarbital (PB; Item Nos. 9001494 | 20987) prevents formation of DEN/PB-induced hepatocellular carcinomas.³ It also reduces liver fibrosis in a rat model of bile duct ligation-induced hepatic fibrosis.⁴

WARNING This product is not for human or veterinary use.

1. Liu, G.T. Bicyclol: A novel drug for treating chronic viral hepatitis B and C. Med. Chem. 5(1), 29-43 (2009).

2. Li, M., and Liu, G.T. Inhibition of Fas/FasL mRNA expression and TNF-a release in concanavalin A-induced liver injury in mice by bicyclol. World J. Gastroenterol. 10(12), 1775-1790 (2004).

3. Yu, L., Wei, H., and Liu, G. A novel antihepatitis drug, bicyclol, prevents liver carcinogenesis in diethylnitrosamine-initiated and phenobarbital-promoted mice tumor model. J. Biomed. Biotechnol. (2012).

4. Zhen, Y.Z., Li, N.R., He, H.W., et al. Protective effect of bicyclol against bile duct ligation-induced hepatic fibrosis in rats. World J. Gastroenterol. 21(23), 7155-7164 (2015).